Abstract
1513 Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: A phase II randomized, double-blind, placebo-controlled pilot trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have